INCan Strengthens Oncology Workforce With Genotyping Unit

Mexico’s National Cancer Institute (INCan) expanded its precision oncology capabilities through the creation of the Genotyping, Digital PCR, Genomics and Bioinformatics Unit, integrating next-generation sequencing, real-time PCR and bioinformatics into clinical workflows. The initiative strengthens Mexico’s molecular diagnostics infrastructure, supporting data-driven cancer treatment, generating genomic evidence for the Mexican population and increasing demand for specialized expertise in oncology, genomics and bioinformatics across the national healthcare system.

Mexico’s National Cancer Institute (INCan) has strengthened its capacity for tumor genotyping with the launch of the Genotyping, Digital PCR, Genomics and Bioinformatics Unit (UniGPGBio), a development that expands the institute’s scientific infrastructure and reinforces the specialized workforce required for precision oncology in the country.

The announcement was made during the institute’s Annual Multidisciplinary Meeting (RAM), where officials presented progress in the technological, methodological and operational implementation of the unit. The initiative represents a strategic component of INCan’s broader effort to consolidate precision medicine in oncology while expanding the institutional capacity needed to support advanced diagnostics and data analysis.

According to Oscar Arrieta, Director General, INCan, the development of the unit reflects sustained institutional work to build the scientific and technical infrastructure required for tumor genotyping. This approach, he said, enables the identification of specific genetic alterations in tumors and supports evidence-based therapeutic decisions.

Arrieta explained that tumor genotyping plays a key role in modern oncology by identifying actionable mutations that can guide the use of targeted therapies. By integrating molecular data into clinical practice, physicians can refine treatment strategies, reduce the use of less effective interventions and improve the alignment between therapy and the biological characteristics of each tumor.

Integrating Advanced Platforms and Specialized Human Capital

The implementation of the unit required the integration of multiple technological platforms and specialized human capital. INCan reports that the incorporation of next-generation sequencing (NGS) technologies, the standardization of real-time PCR techniques and the strengthening of bioinformatics processes have enabled the institute to conduct its first sequencing trials on solid tumors under international molecular and clinical quality standards.

These capabilities also allow the institute to produce genomic reports that can be used directly in clinical decision-making. The generation and interpretation of this data require trained professionals across several disciplines, including molecular biology, genomics, oncology, pathology and computational analysis, highlighting the growing role of specialized labor in the evolution of cancer care.

The development of the UniGPGBio unit also reflects a broader trend in healthcare systems, where precision medicine requires not only advanced technologies but also multidisciplinary teams capable of integrating clinical, laboratory and computational expertise. 

At the institute, collaboration between clinical services, research units, and academic teams has been central to aligning genotyping projects with concrete diagnostic needs. The institute notes that this interdisciplinary approach has already been applied to several clinical areas, including hematological cancers, skin tumors, and soft tissue malignancies, among others.

Beyond its clinical impact, the initiative also contributes to the generation of genomic evidence in the Mexican population. Arrieta emphasized that producing genomic data specific to the country is essential in a healthcare context with distinct epidemiological characteristics, allowing treatment strategies to better reflect the clinical realities faced by Mexican patients.

This effort is expected to support both patient care and research by providing data that can inform future studies and guide the development of therapeutic strategies adapted to the national context.

Through the expansion of its genomic and bioinformatics capabilities, INCan aims to strengthen its role as a reference institution for oncology in Mexico. The institute states that the consolidation of this platform represents an important step toward building a national genotyping infrastructure that can expand access to precision medicine while improving the effectiveness of therapeutic decision-making.

As molecular diagnostics become increasingly integrated into oncology practice, initiatives such as the UniGPGBio unit highlight the growing importance of specialized healthcare labor and scientific infrastructure in supporting the transition toward data-driven cancer care.